Selvita to build PLN 77 mln R&D center in Kraków
18:49
Biotechnology firm Selvita has obtained a building permit for an R&D center in Kraków. The project is estimated to cost PLN 77 million, with PLN 34 million coming from a subsidy from the Ministry of Development. The lab will be operational in H1 2019, the company informed. Selvita plans to invest PLN 390 million in R&D between 2017 and 2021. Selvita develops drugs used in cancer treatment, central nervous system and autoimmune diseases. The company has been listed on the WSE since 2011 (first on the NewConnect market and and since 2014 on the main WSE market).
